Ask OpenScientist

Ask a research question about Mucopolysaccharidosis type IX. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
3
Pathophys.
3
Phenotypes
7
Pathograph
1
Genes
1
Medical Actions
🔗

Mappings

MONDO
MONDO:0011093 mucopolysaccharidosis type 9
skos:exactMatch MONDO
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
MPS IX is inherited in an autosomal recessive manner. The index patient was a compound heterozygote for two HYAL1 mutations, consistent with autosomal recessive segregation reported in the family.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:10339581 SUPPORT Human Clinical
"We identified two mutations in the HYAL1 alleles of the patient, a 1412G --> A mutation that introduces a nonconservative amino acid substitution (Glu268Lys) in a putative active site residue and a complex intragenic rearrangement, 1361del37ins14, that results in a premature termination codon."
The index patient carried two distinct HYAL1 mutations (compound heterozygosity), consistent with autosomal recessive inheritance of MPS IX.

Pathophysiology

3
HYAL1 hyaluronidase deficiency
Biallelic loss-of-function variants in HYAL1 cause deficiency of lysosomal hyaluronidase 1, the endoglycosidase that degrades hyaluronan. Loss of this activity blocks the endoglycosidic breakdown of hyaluronan that is required for its lysosomal turnover.
HYAL1 hgnc:5320
hyaluronan catabolic process GO:0030214 ↓ DECREASED
hyalurononglucosaminidase activity GO:0004415 ↓ DECREASED
Show evidence (2 references)
PMID:10339581 SUPPORT Human Clinical
"The turnover of HA requires endoglycosidic breakdown by lysosomal hyaluronidase, and a congenital deficiency of hyaluronidase has been thought to be incompatible with life."
Establishes that lysosomal hyaluronidase is required for hyaluronan turnover; its congenital deficiency is the proximal defect in MPS IX.
PMID:10339581 SUPPORT Human Clinical
"These genes, HYAL1 and HYAL2, encode two distinct lysosomal hyaluronidases with different substrate specificities."
Identifies HYAL1 as encoding a lysosomal hyaluronidase, the enzyme deficient in MPS IX.
Lysosomal hyaluronan accumulation
Undegraded hyaluronan accumulates within lysosomes. This is the GAG-accumulation hub of the mps_gag_storage module, but unlike the sulfated GAGs, hyaluronan does not engage the heparan-sulfate neuronopathic, dermatan-sulfate somatic, or keratan-sulfate skeletal arms. Hyaluronan is instead enriched in synovial fluid, cartilage, and skin, directing the downstream pathology toward the joints rather than toward the central nervous system, viscera, cornea, or generalized skeleton. This tissue distribution underlies the unexpectedly mild, joint-centred phenotype of MPS IX.
fibroblast CL:0000057 synovial cell CL:0000214 tissue histiocyte (macrophage) CL:0000235
hyaluronan catabolic process GO:0030214 ↓ DECREASED
lysosome GO:0005764
synovial joint UBERON:0002217 synovial fluid UBERON:0001090
Show evidence (2 references)
PMID:10339581 SUPPORT Human Clinical
"Hyaluronan (HA), a large glycosaminoglycan abundant in the extracellular matrix, is important in cell migration during embryonic development, cellular proliferation, and differentiation and has a structural role in connective tissues."
Identifies the stored substrate as hyaluronan, a glycosaminoglycan of the extracellular matrix and connective tissue, distinguishing MPS IX from the sulfated-GAG mucopolysaccharidoses.
PMID:10339581 SUPPORT Human Clinical
"These data provide an explanation for the unexpectedly mild phenotype in mucopolysaccharidosis IX and predict the existence of other hyaluronidase deficiency disorders."
The restricted tissue impact of hyaluronan storage accounts for the unexpectedly mild MPS IX phenotype, consistent with the hub not engaging the sulfated-GAG tissue arms of the module.
Periarticular soft-tissue masses and joint disease
The characteristic clinical expression of MPS IX is periarticular soft-tissue masses with episodic painful joint swelling, together with mild short stature and acetabular erosions. Neurological and visceral involvement are absent. Some later-reported patients are clinically indistinguishable from juvenile idiopathic arthritis, with proliferative synovitis.
synovial joint UBERON:0002217
Show evidence (2 references)
PMID:10339581 SUPPORT Human Clinical
"This patient had a surprisingly mild clinical phenotype, including notable periarticular soft tissue masses, mild short stature, an absence of neurological or visceral involvement, and histological and ultrastructural evidence of a lysosomal storage disease."
Defines the core MPS IX phenotype cluster: periarticular soft-tissue masses and mild short stature, with absent neurological/visceral disease.
PMID:26122630 SUPPORT Human Clinical
"The first reported patient had mild short stature and periarticular soft tissue masses; the other reported patients are clinically indistinguishable from juvenile idiopathic arthritis."
Confirms the joint-centred phenotype across the few reported patients, including a JIA-like presentation in later cases.

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Mucopolysaccharidosis type IX Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

3
Metabolism 2
Periarticular soft-tissue masses Joint swelling HP:0001386
Show evidence (2 references)
PMID:10339581 SUPPORT Human Clinical
"This patient had a surprisingly mild clinical phenotype, including notable periarticular soft tissue masses, mild short stature, an absence of neurological or visceral involvement, and histological and ultrastructural evidence of a lysosomal storage disease."
Directly documents periarticular soft-tissue masses as a defining MPS IX feature.
PMID:26122630 SUPPORT Human Clinical
"The first reported patient had mild short stature and periarticular soft tissue masses; the other reported patients are clinically indistinguishable from juvenile idiopathic arthritis."
Independently confirms periarticular soft-tissue masses in the index MPS IX patient.
Joint swelling Joint swelling HP:0001386
Temporal: RECURRENT
Show evidence (1 reference)
PMID:26122630 SUPPORT Human Clinical
"The first reported patient had mild short stature and periarticular soft tissue masses; the other reported patients are clinically indistinguishable from juvenile idiopathic arthritis."
The JIA-indistinguishable presentation of later patients supports inflammatory joint swelling as part of the MPS IX phenotype.
Growth 1
Short stature Short stature HP:0004322
Severity: MILD
Show evidence (2 references)
PMID:10339581 SUPPORT Human Clinical
"This patient had a surprisingly mild clinical phenotype, including notable periarticular soft tissue masses, mild short stature, an absence of neurological or visceral involvement, and histological and ultrastructural evidence of a lysosomal storage disease."
Directly documents mild short stature as a core MPS IX feature.
PMID:26122630 SUPPORT Human Clinical
"The first reported patient had mild short stature and periarticular soft tissue masses; the other reported patients are clinically indistinguishable from juvenile idiopathic arthritis."
Independently confirms mild short stature in the first reported MPS IX patient.
🧬

Genetic Associations

1
HYAL1 pathogenic variants (Causative)
Gene: HYAL1 hgnc:5320
Autosomal recessive
Show evidence (1 reference)
PMID:10339581 SUPPORT Human Clinical
"We further show that these two hyaluronidase genes, as well as a third recently discovered adjacent hyaluronidase gene, HYAL3, have markedly different tissue expression patterns, consistent with differing roles in HA metabolism."
Documents HYAL1 within the tandem HYAL1/HYAL2/HYAL3 cluster and the distinct tissue expression that underlies the restricted MPS IX phenotype.
💊

Medical Actions

1
Supportive and symptomatic care
Action: supportive care MAXO:0000950
There is no approved enzyme replacement therapy or other disease-modifying treatment for MPS IX. Management is supportive and symptomatic, directed at joint pain, swelling, and the periarticular soft-tissue masses (e.g. analgesia/anti-inflammatory measures and orthopaedic/symptomatic care).
{ }

Source YAML

click to show
name: Mucopolysaccharidosis type IX
creation_date: "2026-06-12T00:00:00Z"
category: Mendelian
description: >-
  Mucopolysaccharidosis type IX (MPS IX, hyaluronidase deficiency, Natowicz
  syndrome) is an extremely rare autosomal recessive lysosomal storage disorder
  caused by deficiency of lysosomal hyaluronidase 1 (HYAL1). Unlike the other
  mucopolysaccharidoses, the stored glycosaminoglycan is hyaluronan (hyaluronic
  acid) rather than a sulfated GAG (dermatan, heparan, or keratan sulfate).
  Because hyaluronan is concentrated in synovial fluid, cartilage, and skin
  rather than in the tissues affected by the sulfated GAGs, MPS IX has a
  surprisingly mild phenotype dominated by periarticular soft-tissue masses,
  episodic painful joint swelling, mild short stature, and acetabular erosions,
  with a notable absence of the neurological, visceral, corneal, and severe
  skeletal involvement seen in the sulfated-GAG mucopolysaccharidoses. Only a
  handful of patients have ever been reported, the first by Natowicz and
  colleagues in 1996. Management is supportive and symptomatic; no enzyme
  replacement therapy is approved.
disease_term:
  preferred_term: Mucopolysaccharidosis type IX
  term:
    id: MONDO:0011093
    label: mucopolysaccharidosis type 9
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0011093
      label: mucopolysaccharidosis type 9
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
parents:
- Mucopolysaccharidosis
- Lysosomal Storage Disorder
synonyms:
- hyaluronidase deficiency
- Natowicz syndrome
- MPS IX
- MPS9
notes: >-
  MPS IX is biochemically distinct from the other mucopolysaccharidoses because
  the undegraded substrate is the non-sulfated glycosaminoglycan hyaluronan,
  not dermatan, heparan, or keratan sulfate. Consequently, the canonical
  sulfated-GAG tissue arms of the mps_gag_storage module (heparan-sulfate
  neuronopathic, dermatan-sulfate somatic/connective-tissue, keratan-sulfate
  skeletal-dysplasia) are not engaged; the periarticular/synovial phenotype of
  MPS IX is an orphan case relative to those arms. Only the GAG-accumulation hub
  of the module is wired here. Hyaluronan is enriched in synovial fluid,
  cartilage, and skin, which is consistent with the joint-centred clinical
  picture. The evidence base is sparse: only a few patients have ever been
  reported, so well-established but minimally documented features (e.g.
  acetabular erosions, autosomal recessive segregation in the index family,
  high serum hyaluronan) are described in prose rather than over-annotated with
  evidence beyond the primary reports.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    MPS IX is inherited in an autosomal recessive manner. The index patient was
    a compound heterozygote for two HYAL1 mutations, consistent with autosomal
    recessive segregation reported in the family.
  evidence:
  - reference: PMID:10339581
    reference_title: "Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified two mutations in the HYAL1 alleles of the patient, a 1412G --> A mutation that introduces a nonconservative amino acid substitution (Glu268Lys) in a putative active site residue and a complex intragenic rearrangement, 1361del37ins14, that results in a premature termination codon."
    explanation: >-
      The index patient carried two distinct HYAL1 mutations (compound
      heterozygosity), consistent with autosomal recessive inheritance of MPS IX.
pathophysiology:
- name: HYAL1 hyaluronidase deficiency
  description: >-
    Biallelic loss-of-function variants in HYAL1 cause deficiency of lysosomal
    hyaluronidase 1, the endoglycosidase that degrades hyaluronan. Loss of this
    activity blocks the endoglycosidic breakdown of hyaluronan that is required
    for its lysosomal turnover.
  genes:
  - preferred_term: HYAL1
    term:
      id: hgnc:5320
      label: HYAL1
  molecular_functions:
  - preferred_term: hyalurononglucosaminidase activity
    modifier: DECREASED
    term:
      id: GO:0004415
      label: hyalurononglucosaminidase activity
  biological_processes:
  - preferred_term: hyaluronan catabolic process
    modifier: DECREASED
    term:
      id: GO:0030214
      label: hyaluronan catabolic process
  evidence:
  - reference: PMID:10339581
    reference_title: "Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The turnover of HA requires endoglycosidic breakdown by lysosomal hyaluronidase, and a congenital deficiency of hyaluronidase has been thought to be incompatible with life."
    explanation: >-
      Establishes that lysosomal hyaluronidase is required for hyaluronan
      turnover; its congenital deficiency is the proximal defect in MPS IX.
  - reference: PMID:10339581
    reference_title: "Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These genes, HYAL1 and HYAL2, encode two distinct lysosomal hyaluronidases with different substrate specificities."
    explanation: >-
      Identifies HYAL1 as encoding a lysosomal hyaluronidase, the enzyme
      deficient in MPS IX.
  downstream:
  - target: Lysosomal hyaluronan accumulation
    causal_link_type: DIRECT
    description: >-
      Loss of hyaluronidase 1 activity leaves hyaluronan undegraded, so it
      accumulates within lysosomes.
    evidence:
    - reference: PMID:10339581
      reference_title: "Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This patient had a surprisingly mild clinical phenotype, including notable periarticular soft tissue masses, mild short stature, an absence of neurological or visceral involvement, and histological and ultrastructural evidence of a lysosomal storage disease."
      explanation: >-
        Histological and ultrastructural evidence of lysosomal storage in the
        hyaluronidase-deficient patient supports lysosomal accumulation of the
        undegraded substrate.
- name: Lysosomal hyaluronan accumulation
  conforms_to: "mps_gag_storage#Lysosomal GAG Accumulation"
  description: >-
    Undegraded hyaluronan accumulates within lysosomes. This is the
    GAG-accumulation hub of the mps_gag_storage module, but unlike the sulfated
    GAGs, hyaluronan does not engage the heparan-sulfate neuronopathic,
    dermatan-sulfate somatic, or keratan-sulfate skeletal arms. Hyaluronan is
    instead enriched in synovial fluid, cartilage, and skin, directing the
    downstream pathology toward the joints rather than toward the
    central nervous system, viscera, cornea, or generalized skeleton. This
    tissue distribution underlies the unexpectedly mild, joint-centred phenotype
    of MPS IX.
  chemical_entities:
  - preferred_term: hyaluronan
    term:
      id: CHEBI:16336
      label: hyaluronic acid
    modifier: INCREASED
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: synovial cell
    term:
      id: CL:0000214
      label: synovial cell
  - preferred_term: tissue histiocyte (macrophage)
    term:
      id: CL:0000235
      label: macrophage
  locations:
  - preferred_term: synovial joint
    term:
      id: UBERON:0002217
      label: synovial joint
  - preferred_term: synovial fluid
    term:
      id: UBERON:0001090
      label: synovial fluid
  biological_processes:
  - preferred_term: hyaluronan catabolic process
    modifier: DECREASED
    term:
      id: GO:0030214
      label: hyaluronan catabolic process
  evidence:
  - reference: PMID:10339581
    reference_title: "Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hyaluronan (HA), a large glycosaminoglycan abundant in the extracellular matrix, is important in cell migration during embryonic development, cellular proliferation, and differentiation and has a structural role in connective tissues."
    explanation: >-
      Identifies the stored substrate as hyaluronan, a glycosaminoglycan of the
      extracellular matrix and connective tissue, distinguishing MPS IX from the
      sulfated-GAG mucopolysaccharidoses.
  - reference: PMID:10339581
    reference_title: "Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These data provide an explanation for the unexpectedly mild phenotype in mucopolysaccharidosis IX and predict the existence of other hyaluronidase deficiency disorders."
    explanation: >-
      The restricted tissue impact of hyaluronan storage accounts for the
      unexpectedly mild MPS IX phenotype, consistent with the hub not engaging
      the sulfated-GAG tissue arms of the module.
  downstream:
  - target: Periarticular soft-tissue masses and joint disease
    causal_link_type: DIRECT
    description: >-
      Hyaluronan storage in and around joints produces periarticular
      soft-tissue masses and joint disease.
    evidence:
    - reference: PMID:10339581
      reference_title: "Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This patient had a surprisingly mild clinical phenotype, including notable periarticular soft tissue masses, mild short stature, an absence of neurological or visceral involvement, and histological and ultrastructural evidence of a lysosomal storage disease."
      explanation: >-
        Directly links the hyaluronidase-deficiency storage state to
        periarticular soft-tissue masses and the broader mild joint-centred
        phenotype.
- name: Periarticular soft-tissue masses and joint disease
  description: >-
    The characteristic clinical expression of MPS IX is periarticular
    soft-tissue masses with episodic painful joint swelling, together with mild
    short stature and acetabular erosions. Neurological and visceral involvement
    are absent. Some later-reported patients are clinically indistinguishable
    from juvenile idiopathic arthritis, with proliferative synovitis.
  locations:
  - preferred_term: synovial joint
    term:
      id: UBERON:0002217
      label: synovial joint
  evidence:
  - reference: PMID:10339581
    reference_title: "Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This patient had a surprisingly mild clinical phenotype, including notable periarticular soft tissue masses, mild short stature, an absence of neurological or visceral involvement, and histological and ultrastructural evidence of a lysosomal storage disease."
    explanation: >-
      Defines the core MPS IX phenotype cluster: periarticular soft-tissue
      masses and mild short stature, with absent neurological/visceral disease.
  - reference: PMID:26122630
    reference_title: "Screening Mucopolysaccharidosis Type IX in Patients with Juvenile Idiopathic Arthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The first reported patient had mild short stature and periarticular soft tissue masses; the other reported patients are clinically indistinguishable from juvenile idiopathic arthritis."
    explanation: >-
      Confirms the joint-centred phenotype across the few reported patients,
      including a JIA-like presentation in later cases.
  downstream:
  - target: Periarticular soft-tissue masses
    causal_link_type: DIRECT
    description: Hyaluronan storage produces periarticular soft-tissue masses.
  - target: Joint swelling
    causal_link_type: DIRECT
    description: Joint-centered hyaluronan storage manifests as episodic painful joint swelling.
  - target: Short stature
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: The joint-centered lysosomal storage phenotype includes mild short stature.
phenotypes:
- name: Periarticular soft-tissue masses
  category: Musculoskeletal
  description: >-
    Notable periarticular soft-tissue masses, accompanied by episodes of painful
    joint swelling, are the hallmark feature of MPS IX. No precise HPO term
    exists for periarticular soft-tissue masses, so this is annotated to the
    closest available term, Joint swelling.
  phenotype_term:
    preferred_term: Periarticular soft-tissue masses with joint swelling
    term:
      id: HP:0001386
      label: Joint swelling
  evidence:
  - reference: PMID:10339581
    reference_title: "Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This patient had a surprisingly mild clinical phenotype, including notable periarticular soft tissue masses, mild short stature, an absence of neurological or visceral involvement, and histological and ultrastructural evidence of a lysosomal storage disease."
    explanation: >-
      Directly documents periarticular soft-tissue masses as a defining MPS IX
      feature.
  - reference: PMID:26122630
    reference_title: "Screening Mucopolysaccharidosis Type IX in Patients with Juvenile Idiopathic Arthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The first reported patient had mild short stature and periarticular soft tissue masses; the other reported patients are clinically indistinguishable from juvenile idiopathic arthritis."
    explanation: >-
      Independently confirms periarticular soft-tissue masses in the index MPS IX
      patient.
- name: Short stature
  category: Growth
  description: >-
    Mild short stature is part of the MPS IX phenotype and is notably milder than
    the disproportionate short stature of the sulfated-GAG mucopolysaccharidoses.
  phenotype_term:
    preferred_term: Mild short stature
    term:
      id: HP:0004322
      label: Short stature
    severity: MILD
  evidence:
  - reference: PMID:10339581
    reference_title: "Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This patient had a surprisingly mild clinical phenotype, including notable periarticular soft tissue masses, mild short stature, an absence of neurological or visceral involvement, and histological and ultrastructural evidence of a lysosomal storage disease."
    explanation: >-
      Directly documents mild short stature as a core MPS IX feature.
  - reference: PMID:26122630
    reference_title: "Screening Mucopolysaccharidosis Type IX in Patients with Juvenile Idiopathic Arthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The first reported patient had mild short stature and periarticular soft tissue masses; the other reported patients are clinically indistinguishable from juvenile idiopathic arthritis."
    explanation: >-
      Independently confirms mild short stature in the first reported MPS IX
      patient.
- name: Joint swelling
  category: Musculoskeletal
  description: >-
    Episodic painful joint swelling occurs in MPS IX, sometimes mimicking
    juvenile idiopathic arthritis with proliferative synovitis.
  phenotype_term:
    preferred_term: Episodic painful joint swelling
    term:
      id: HP:0001386
      label: Joint swelling
    temporality: RECURRENT
  evidence:
  - reference: PMID:26122630
    reference_title: "Screening Mucopolysaccharidosis Type IX in Patients with Juvenile Idiopathic Arthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The first reported patient had mild short stature and periarticular soft tissue masses; the other reported patients are clinically indistinguishable from juvenile idiopathic arthritis."
    explanation: >-
      The JIA-indistinguishable presentation of later patients supports
      inflammatory joint swelling as part of the MPS IX phenotype.
genetic:
- name: HYAL1 pathogenic variants
  gene_term:
    preferred_term: HYAL1
    term:
      id: hgnc:5320
      label: HYAL1
  association: Causative
  inheritance:
  - name: Autosomal recessive
    description: >-
      MPS IX results from biallelic HYAL1 variants; the index patient was a
      compound heterozygote.
    evidence:
    - reference: PMID:10339581
      reference_title: "Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We identified two mutations in the HYAL1 alleles of the patient, a 1412G --> A mutation that introduces a nonconservative amino acid substitution (Glu268Lys) in a putative active site residue and a complex intragenic rearrangement, 1361del37ins14, that results in a premature termination codon."
      explanation: >-
        Two distinct HYAL1 alleles in the patient support biallelic (compound
        heterozygous) autosomal recessive disease.
  features: >-
    MPS IX is caused by biallelic loss-of-function variants in HYAL1, which
    encodes lysosomal hyaluronidase 1. The originally described patient was a
    compound heterozygote for a missense variant affecting a putative active-site
    residue (Glu268Lys) and a complex intragenic rearrangement producing a
    premature termination codon. HYAL1 and the adjacent HYAL2/HYAL3 genes have
    distinct tissue expression patterns, which helps explain why HYAL1 deficiency
    produces such a restricted, mild phenotype.
  evidence:
  - reference: PMID:10339581
    reference_title: "Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We further show that these two hyaluronidase genes, as well as a third recently discovered adjacent hyaluronidase gene, HYAL3, have markedly different tissue expression patterns, consistent with differing roles in HA metabolism."
    explanation: >-
      Documents HYAL1 within the tandem HYAL1/HYAL2/HYAL3 cluster and the
      distinct tissue expression that underlies the restricted MPS IX phenotype.
treatments:
- name: Supportive and symptomatic care
  description: >-
    There is no approved enzyme replacement therapy or other disease-modifying
    treatment for MPS IX. Management is supportive and symptomatic, directed at
    joint pain, swelling, and the periarticular soft-tissue masses (e.g.
    analgesia/anti-inflammatory measures and orthopaedic/symptomatic care).
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
prevalence:
- population: Worldwide
  notes: >-
    MPS IX is the rarest mucopolysaccharidosis; only a handful of patients have
    ever been reported in the literature.
  evidence:
  - reference: PMID:26122630
    reference_title: "Screening Mucopolysaccharidosis Type IX in Patients with Juvenile Idiopathic Arthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mucopolysaccharidosis type IX is the rarest form of mucopolysaccharidosis. To date, only four patients have been reported."
    explanation: >-
      Directly supports the extreme rarity of MPS IX.